Fig. 4From: Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trialsAdverse reactions to COVID-19 vaccines between population aged ≤ 55 years and population aged ≥ 56 years. *COVID-19 vaccines on first vaccination; **COVID-19 vaccines on second vaccination; b1BNT162b1 in the Phase I Trial; b2BNT162b2 in the Phase I Trial. CI confidence interval, mRNA messenger ribonucleic acidBack to article page